Top questions on FDA’s proposed LDT rule: Carve outs, capacity and quality systems

A month after the FDA published its proposed rule to enforce regulatory requirements on laboratory developed tests (LDTs), AgencyIQ has some outstanding questions. In particular – potential issues with applying the policy to practice, the role of different stakeholders and the new proposed definitions.

Fill out the form to read the full article.

Required *

Copy link
Powered by Social Snap